Common Stock, Shares, Issued of CRISPR Therapeutics AG from Q4 2015 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Summary
CRISPR Therapeutics AG quarterly Common Stock, Shares, Issued history and change rate from Q4 2015 to Q3 2025.
  • CRISPR Therapeutics AG Common Stock, Shares, Issued for the quarter ending 30 Sep 2025 was 94M shares, a 9.93% increase year-over-year.
Common Stock, Shares, Issued, Quarterly (shares)
Common Stock, Shares, Issued, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Common Stock, Shares, Issued (shares)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 94M +8.49M +9.93% 30 Sep 2025 10-Q 10 Nov 2025
Q2 2025 88.5M +3.33M +3.91% 30 Jun 2025 10-Q 04 Aug 2025
Q1 2025 86.5M +1.52M +1.79% 31 Mar 2025 10-Q 06 May 2025
Q4 2024 85.9M +5.7M +7.1% 31 Dec 2024 10-Q 10 Nov 2025
Q3 2024 85.5M +5.9M +7.41% 30 Sep 2024 10-Q 05 Nov 2024
Q2 2024 85.2M +5.66M +7.12% 30 Jun 2024 10-Q 05 Aug 2024
Q1 2024 85M +5.96M +7.55% 31 Mar 2024 10-Q 08 May 2024
Q4 2023 80.2M +1.52M +1.93% 31 Dec 2023 10-K 11 Feb 2025
Q3 2023 79.6M +1.18M +1.5% 30 Sep 2023 10-Q 06 Nov 2023
Q2 2023 79.6M +1.58M +2.03% 30 Jun 2023 10-Q 07 Aug 2023
Q1 2023 79M +1.48M +1.91% 31 Mar 2023 10-Q 08 May 2023
Q4 2022 78.7M +1.52M +1.97% 31 Dec 2022 10-K 21 Feb 2024
Q3 2022 78.4M +1.78M +2.33% 30 Sep 2022 10-Q 01 Nov 2022
Q2 2022 78M +1.7M +2.23% 30 Jun 2022 10-Q 08 Aug 2022
Q1 2022 77.6M +1.64M +2.16% 31 Mar 2022 10-Q 09 May 2022
Q4 2021 77.2M +3.06M +4.13% 31 Dec 2021 10-K 21 Feb 2023
Q3 2021 76.6M +5.84M +8.26% 30 Sep 2021 10-Q 03 Nov 2021
Q2 2021 76.3M +13.5M +21.6% 30 Jun 2021 10-Q 29 Jul 2021
Q1 2021 75.9M +14.8M +24.2% 31 Mar 2021 10-Q 27 Apr 2021
Q4 2020 74.1M +13.1M +21.4% 31 Dec 2020 10-K 15 Feb 2022
Q3 2020 70.8M +15.4M +27.7% 30 Sep 2020 10-Q 28 Oct 2020
Q2 2020 62.7M +8.99M +16.7% 30 Jun 2020 10-Q 27 Jul 2020
Q1 2020 61.1M +8.18M +15.4% 31 Mar 2020 10-Q 28 Apr 2020
Q4 2019 61M +8.87M +17% 31 Dec 2019 10-K 16 Feb 2021
Q3 2019 55.4M +3.58M +6.91% 30 Sep 2019 10-Q 28 Oct 2019
Q2 2019 53.8M +6.27M +13.2% 30 Jun 2019 10-Q 29 Jul 2019
Q1 2019 52.9M +5.82M +12.4% 31 Mar 2019 10-Q 29 Apr 2019
Q4 2018 52.2M +11.1M +27.1% 31 Dec 2018 10-K 12 Feb 2020
Q3 2018 51.9M +11M +27% 30 Sep 2018 10-Q 07 Nov 2018
Q2 2018 47.5M +7M +17.3% 30 Jun 2018 10-Q 07 Aug 2018
Q1 2018 47.1M 31 Mar 2018 10-Q 08 May 2018
Q4 2017 41M +873K +2.17% 31 Dec 2017 10-K 25 Feb 2019
Q3 2017 40.8M +35.2M +621% 30 Sep 2017 10-Q 08 Nov 2017
Q2 2017 40.5M 30 Jun 2017 10-Q 10 Aug 2017
Q4 2016 40.2M +34.6M +627% 31 Dec 2016 10-K 08 Mar 2018
Q3 2016 5.66M 30 Sep 2016 10-Q 22 Nov 2016
Q4 2015 5.53M 31 Dec 2015 10-K 10 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.